

MD Anderson Ovarian SPORE publications – 2016

1. Bowser JL, Broaddus RR. CD73s protection of epithelial integrity: **Thinking beyond the barrier**. *Tissue Barriers* 4(4):e1224963, 2016. PMID: PMC5214510.
2. Callegaro-Filho D, Gershenson DM, Nick AM, Munsell MF, Ramirez PT, Eifel PJ, Euscher ED, Marques RM, Nicolau SM, Schmeler KM. **Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): A review of 47 cases**. *Gynecol Oncol* 140(1):53-7, 2016. PMID: 26546963.
3. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB. **Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer**. *Cell Rep* 15(7):1493-1504, 2016. PMID: PMC4914391.
4. Cheung LW, Mills GB. **Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment**. *Pharmacogenomics* 17(3):297-307, 2016. PMID: PMC5558511.
5. Coleman RL. **Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care**. *Nat Rev Clin Oncol* 13(2):71-2, 2016. PMID: 26718108.
6. Daniels MS, Lu KH. **Genetic predisposition in gynecologic cancers**. *Semin Oncol* 43(5):543-547, 2016. PMID: 27899185.
7. Dao F, Schluppe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA. **Characteristics of 10-year survivors of high-grade serous ovarian carcinoma**. *Gynecol Oncol* 141(2):260-263, 2016. PMID: PMC4844793.
8. Doeckel JD, Wang Y, Baggerly K. **Co-localized genomic regulation of miRNA and mRNA via DNA methylation affects survival in multiple tumor types**. *Cancer Genet* 209(10):463-473, 2016. PMID: 27810075.
9. Dwivedi SK, Mustafi SB, Mangala LS, Jiang D, Pradeep S, Rodriguez-Aguayo C, Ling H, Ivan C, Mukherjee P, Calin GA, Lopez-Berestein G, Sood AK, Bhattacharya R. **Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer**. *Oncotarget* 7(12):15093-104, 2016. PMID: PMC4924772.
10. Ejaz A, Mitterberger MC, Lu Z, Mattesich M, Zwierzina ME, Hörl S, Kaiser A, Viertler HP, Rostek U, Meryk A, Khalid S, Pierer G, Bast RC Jr, Zwerschke W. **Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition**. *EBioMedicine* 6:149-161, 2016. PMID: PMC4856797.
11. Feng S, Kroll MH, Nick AM, Sood AK, Afshar-Kharghan V. **Platelets are not hyperreactive in patients with ovarian cancer**. *Platelets* 27(7):716-718, 2016. PMID: PMC5184822.
12. Ganeshan D, Bhosale P, Wei W, Ramalingam P, Mudasiru-Dawodu E, Gershenson D, Sun C, Iyer R. **Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer**. *Abdom Radiol (NY)* 41(8):1589-95, 2016. PMID: PMC4974160.
13. Gershenson DM, Frazier AL. **Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment**. *Gynecol Oncol* 143(2):428-432, 2016. PMID: 27569583.
14. Gershenson DM. **Low-grade serous carcinoma of the ovary or peritoneum**. *Ann Oncol* 27 Suppl 1:i45-i49, 2016. PMID: 27141071.
15. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B,

Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. **FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.** J Clin Invest 126(5):1885-96, 2016. PMID: PMC4855933.

16. Han HD, Byeon Y, Jang JH, Jeon HN, Kim GH, Kim MG, Pack CG, Kang TH, Jung ID, Lim YT, Lee YJ, Lee JW, Shin BC, Ahn HJ, Sood AK, Park YM. **In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.** Sci Rep 6:38348, 2016. PMID: PMC5133713.
17. Han HD, Byeon Y, Kang TH, Jung ID, Lee JW, Shin BC, Lee YJ, Sood AK, Park YM. **Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.** Int J Nanomedicine 11:5729-5742, 2016. PMID: PMC5098754.
18. Hansen JM, Coleman RL, Sood AK. **Targeting the tumour microenvironment in ovarian cancer.** Eur J Cancer 56:131-143, 2016. PMID: PMC4769921.
19. Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, Court KA, Liu T, Nie S, Rodriguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Jennings N, Shim J, Dorniak PL, Mangala LS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, Lopez-Berestein G, Li C, Sood AK. **Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.** Cell Rep 17(6):1621-1631, 2016. PMID: PMC5123842.
20. He N, Kim N, Jeong E, Lu Y, Mills GB, Yoon S. **Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines.** Int J Oncol 48(1):67-72, 2016. PMID: PMC4734611.
21. Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F. **MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.** Clin Cancer Res 22(4):935-47, 2016. PMID: PMC4755805.
22. Hou MM, Wang Z, Janku F, Piha-Paul S, Naing A, Hong D, Westin S, Coleman RL, Sood AK, Tsimberidou AM, Subbiah V, Wheler J, Zinner R, Lu K, Meric-Bernstam F, Fu S. **Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.** Oncotarget 7(23):35132-43, 2016. PMID: PMC5085215.
23. Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V. **Lipid profile of platelets and platelet-derived microparticles in ovarian cancer.** BBA Clin 6:76-81, 2016. PMID: PMC4941562.
24. Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. **DII4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.** Mol Cancer Ther 15(6):1344-52, 2016. PMID: PMC4893925.
25. Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Dorniak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK. **Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.** Mol Cancer Ther 15(12):2894-2904, 2016. PMID: PMC5136300.
26. Jenner ZB, Sood AK, Coleman RL. **Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.** Future Oncol 12(12):1439-56, 2016. PMID: PMC4976841.
27. Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez-Aguayo C, Bayraktar E, Pichler M, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. **Ubiquitous**

Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res 76(24):7194-7207, 2016. PMID: 27742688.

28. Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. **Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group.** Cancer Res 76(13):3671-5, 2016. PMID: 27527638.
29. Leung F, Bernardini MQ, Brown MD, Zheng Y, Molina R, Bast RC Jr, Davis G, Serra S, Diamandis EP, Kulasingam V. **Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.** Cancer Epidemiol Biomarkers Prev 25(9):1333-40, 2016. PMCID: PMC5010461.
30. Liang L, Jiang Y, Chen JS, Niu N, Piao J, Ning J, Zu Y, Zhang J, Liu J. **B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.** Hum Pathol 57:1-6, 2016. PMCID: PMC5077670.
31. Liang L, Olar A, Niu N, Jiang Y, Cheng W, Bian XW, Yang W, Zhang J, Yemelyanova A, Malpica A, Zhang Z, Fuller GN, Liu J. **Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases.** Am J Surg Pathol 40(6):847-56, 2016. PMCID: PMC4864123.
32. Liu J, Westin SN. **Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.** Gynecol Oncol 141(1):65-71, 2016. PMCID: PMC4808566.
33. Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladiëff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E. **Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.** J Clin Oncol 34(36):4345-4353, 2016. PMCID: PMC5562430.
34. Lu Y, Ling S, Hegde AM, Byers LA, Coombes K, Mills GB, Akbani R. **Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.** Semin Oncol 43(4):476-83, 2016. PMCID: PMC5111873.
35. Malpica A, Wong KK. **The molecular pathology of ovarian serous borderline tumors.** Ann Oncol 27 Suppl 1:i16-i19, 2016. PMCID: PMC4852276.
36. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X, Haemmerle M, Rodriguez-Aguayo C, Nagaraja AS, Rupaimoole R, Bayraktar E, Bayraktar R, Li L, Tanaka T, Hu W, Ivan C, Gharpure KM, McGuire MH, Thiviyanathan V, Zhang X, Maiti SN, Bulayeva N, Choi HJ, Dorniak PL, Cooper LJ, Rosenblatt KP, Lopez-Berestein G, Gorenstein DG, Sood AK. **Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy.** JCI Insight 1(17):e87754, 2016. PMCID: PMC5070952.
37. Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, Shaw K, Lu K, Qi Y, Zhao H, Lara-Guerra H, Litton J, Arun B, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies MA, Kopetz S, Mendelsohn J, Mills GB, Chen K. **Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.** Ann Oncol 27(5):795-800, 2016. PMCID: PMC4843184.
38. Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, Bivona S, Dhar S, Bast RC Jr, Saya H, Choi HG, Gray NS, Fischer R, Kessler BM, Yau C, Sood AK, Motohara T, Knapp S, Ahmed AA. **Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.** Cancer Cell 30(2):273-289, 2016. PMID: 27478041.

39. Mitamura T, Gourley C, Sood AK. **Prediction of anti-angiogenesis escape.** *Gynecol Oncol* 141(1):80-5, 2016. PMID: PMC4808422.
40. Monk BJ, Minion LE, Coleman RL. **Anti-angiogenic agents in ovarian cancer: past, present, and future.** *Ann Oncol* 27 Suppl 1:i33-i39, 2016. PMID: 27141068.
41. Monk BJ, Sill MW, Walker JL, Darus CJ, Sutton G, Tewari KS, Martin LP, Schilder JM, Coleman RL, Balkissoon J, Aghajanian C. **Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.** *J Clin Oncol* 34(19):2279-86, 2016. PMID: PMC4962710.
42. Moruno-Manchon JF, Uzor NE, Kesler SR, Wefel JS, Townley DM, Nagaraja AS, Pradeep S, Mangala LS, Sood AK, Tsvetkov AS. **TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin.** *Aging (Albany NY)* 8(12):3507-3519, 2016. PMID: PMC5270683.
43. Muranen T, Selfors LM, Hwang J, Gallegos LL, Coloff JL, Thoreen CC, Kang SA, Sabatini DM, Mills GB, Brugge JS. **ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.** *Cancer Res* 76(24):7168-7180, 2016. PMID: PMC5161652.
44. Nagaraja AS, Dorniak PL, Sadaoui NC, Kang Y, Lin T, Armaiz-Pena G, Wu SY, Rupaimoole R, Allen JK, Gharpure KM, Pradeep S, Zand B, Previs RA, Hansen JM, Ivan C, Rodriguez-Aguayo C, Yang P, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. **Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.** *Oncogene* 35(18):2390-7, 2016. PMID: PMC4749473.
45. Nishizuka SS, Mills GB. **New era of integrated cancer biomarker discovery using reverse-phase protein arrays.** *Drug Metab Pharmacokinet* 31(1):35-45, 2016. PMID: 26822993.
46. Niu N, Zhang J, Zhang N, Mercado-Uribe I, Tao F, Han Z, Pathak S, Multani AS, Kuang J, Yao J, Bast RC, Sood AK, Hung MC, Liu J. **Linking genomic reorganization to tumor initiation via the giant cell cycle.** *Oncogenesis* 5(12):e281, 2016. PMID: PMC5177773.
47. Ornelas A, McCullough CR, Lu Z, Zacharias NM, Kelderhouse LE, Gray J, Yang H, Engel BJ, Wang Y, Mao W, Sutton MN, Bhattacharya PK, Bast RC Jr, Millward SW. **Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.** *BMC Cancer* 16(1):824, 2016. PMID: PMC5080741.
48. Pashankar F, Hale JP, Dang H, Krailo M, Brady WE, Rodriguez-Galindo C, Nicholson JC, Murray MJ, Bilmire DF, Stoneham S, Arul GS, Olson TA, Stark D, Shaikh F, Amatruda JF, Covens A, Gershenson DM, Frazier AL. **Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative.** *Cancer* 122(2):230-7, 2016. PMID: PMC5134834.
49. Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z, AOCS Study Group., Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vanderstichele A, Van Niewenhuyse E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Moysich K, Odunsi K, Goodman MT, Shvetsov YB, Wilkens LR, Thompson PJ, Dörk T, Bogdanova N, Butzow R, Nevanlinna H, Pelttari L, Leminen A, Modugno F, Edwards RP, Ness RB, Kelley J, Heitz F, Karlan B, Lester J, Kjaer SK, Jensen A, Giles G, Hildebrandt M, Liang D, Lu KH, Wu X, Levine DA, Bisogna M, Berchuck A, Cramer DW, Terry KL, Tworoger SS, Poole EM, Bandera EV, Fridley B, Cunningham J, Winham SJ, Olson SH, Orlow I, Bjorge L, Kiemeny LA, Massuger L, Pejovic T, Moffitt M, Le N, Cook LS, Brooks-Wilson A, Kelemen LE, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Yang H, Hogdall E, Hogdall C, Lundvall L, Pharoah PD, Song H, Campbell I, Eccles D, McNeish I, Whittemore A, McGuire V, Sieh W, Rothstein J, Phelan CM, Risch H, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Dansonka-Mieszkowska A, Schildkraut JM, Cheng JQ, Goode EL,

Sellers TA. **Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.** *Oncotarget* 7(45):72381-72394, 2016. PMID: PMC5340123.

50. Previs RA, Sood AK, Mills GB, Westin SN. **The rise of genomic profiling in ovarian cancer.** *Expert Rev Mol Diagn* 16(12):1337-1351, 2016. PMID: PMC5659206.
51. Rytelowski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD. **Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.** *Oncotarget* 7(15):20825-39, 2016. PMID: PMC4991495.
52. Schultz KA, Harris AK, Schneider DT, Young RH, Brown J, Gershenson DM, Dehner LP, Hill DA, Messinger YH, Frazier AL. **Ovarian Sex Cord-Stromal Tumors.** *J Oncol Pract* 12(10):940-946, 2016. PMID: PMC5063189.
53. Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, Zhang Z, Bast RC Jr, Skates SJ. **Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer.** *Int J Gynecol Cancer* 26(6):1070-7, 2016. PMID: PMC4915986.
54. Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. **Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.** *Int J Gynecol Cancer* 26(1):43-51, 2016. PMID: PMC4679342.
55. Takekuma M, Wong KK, Coleman RL. **A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.** *Gynecol Oncol Res Pract* 3:5, 2016. PMID: PMC4880811.
56. Thaker PH, Urbauer DL, Sood AK. **Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?** *Cancer* 122(2):325-6, 2016. PMID: 26443929.
57. Wang C, Zhu X, Feng W, Yu Y, Jeong K, Guo W, Lu Y, Mills GB. **Verteporfin inhibits YAP function through up-regulating 14-3-3 σ sequestering YAP in the cytoplasm.** *Am J Cancer Res* 6(1):27-37, 2016. PMID: PMC4759394.
58. Wang H, Li X, Volk DE, Lokesh GL, Elizondo-Riojas MA, Li L, Nick AM, Sood AK, Rosenblatt KP, Gorenstein DG. **Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.** *Biotechniques* 61(5):249-259, 2016. PMID: PMC5136366.
59. Whiting N, Hu J, Zacharias NM, Lokesh GL, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya P. **Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer.** *J Med Imaging (Bellingham)* 3(3):036001, 2016. PMID: PMC4979585.
60. Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. **A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.** *Nat Commun* 7:11169, 2016. PMID: PMC4822037.
61. Xiao X, Yang G, Bai P, Gui S, Nyuyen TM, Mercado-Uribe I, Yang M, Zou J, Li Q, Xiao J, Chang B, Liu G, Wang H, Liu J. **Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.** *BMC Cancer* 16:582, 2016. PMID: PMC4971665.

62. Yang H, Das P, Yu Y, Mao W, Wang Y, Baggerly K, Wang Y, Marquez RT, Bedi A, Liu J, Fishman D, Lu Z, Bast RC Jr. **NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.** *Oncotarget* 7(3):3018-32, 2016. PMID: PMC4823087.
63. Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D. **Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.** *Cell Metab* 24(5):685-700, 2016. PMID: 27829138.
64. Yokoyama Y, Zhu H, Lee JH, Kossenkov AV, Wu SY, Wickramasinghe JM, Yin X, Palozola KC, Gardini A, Showe LC, Zaret KS, Liu Q, Speicher D, Conejo-Garcia JR, Bradner JE, Zhang Z, Sood AK, Ordog T, Bitler BG, Zhang R. **BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.** *Cancer Res* 76(21):6320-6330, 2016. PMID: PMC5117661.
65. Zand B, Previs RA, Zacharias NM, Rupaimoole R, Mitamura T, Nagaraja AS, Guindani M, Dalton HJ, Yang L, Baddour J, Achreja A, Hu W, Pecot CV, Ivan C, Wu SY, McCullough CR, Gharpure KM, Shoshan E, Pradeep S, Mangala LS, Rodriguez-Aguayo C, Wang Y, Nick AM, Davies MA, Armaiz-Pena G, Liu J, Lutgendorf SK, Baggerly KA, Eli MB, Lopez-Berestein G, Nagrath D, Bhattacharya PK, Sood AK. **Role of Increased n-acetylaspartate Levels in Cancer.** *J Natl Cancer Inst* 108(6):djv426, 2016. PMID: PMC4849357.
66. Zhang L, Yuan Y, Lu KH, Zhang L. **Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer.** *BMC Bioinformatics* 17(1):222, 2016. PMID: PMC4881176.
67. Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D. **Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.** *Gynecol Oncol* 141(1):57-64, 2016. PMID: PMC4967351.
68. Zhang S, Mercado-Uribe I, Sood A, Bast RC, Liu J. **Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells.** *Genes Cancer* 7(3-4):60-72, 2016. PMID: PMC4918945.